Thursday, 20 Feb 2020

You are here

Omega-3 Rich Fish Lowers Gout Flares

Boston researchers have shown that consumption of fish rich in omega‐3 polyunsaturated fatty acids (n‐3 PUFA) leads to a lower risk of recurrent gout flares.

They used a novel internet‐based, case‐crossover study conducted from 2003‐2012 (the Boston University Online Gout Study). They questioned gout patients about gout flares, and during gout flare‐free periods their intake of n‐3 PUFA‐rich supplements and fish intake, total purine intake, diuretic use, and other arthritis and urate‐lowering medications (allopurinol, non‐steroidal anti‐inflammatory drugs, colchicine).

Of the 724 participants, 85% met the 1977 Preliminary ACR classification criteria for acute gout.

In all patients (flare and non-flare; n=724 patients), 22% reported ingesting form of n‐3 PUFA consumption (supplements: 4.6%; dietary fatty fish: 19%) in the prior 48 hours. 

While any ingestion of n-3 PUFA did not affect gout flares (aOR 1.01; 95% CI, 0.63‐1.60; p=0.98), those who had two or more servings of n‐3 PUFA‐rich fish had a lower risk of gout flares (aOR 0.74; 95% CI, 0.54‐0.99; p=0.04).

Supplement use with either Omega 3, cod liver oil or fish oil supplements did not lower the risk of recurrent gout flares.


The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Hypersensitivity Reactions and Gout Tx: Watch the Dose

Both allopurinol and febuxostat (Uloric) were associated with an increased risk of hypersensitivity reactions among new users of these urate-lowering therapies, a large U.S. study found.

Diabetics using SGLT2 Inhibitors have a lower Gout Risk

Researchers from the Brigham and Women's Hospital have reported that adults with type 2 diabetes who were treated with SGLT2 inhibitors had a lower risk of gout compared to GLP1 agonist, suggesting that sodium–glucose cotransporter-2 inhibitors may reduce the risk for gout with type 2 diabetes mellitus (T2DM).

A Role for SGLT2 Inhibition in Gout?

The antidiabetic medication canagliflozin (Invokana) lowered serum urate and reduced the risk of gout flare in a post-hoc analysis of data from two large clinical trials.

Predicting Inpatient Gout Flares

Analysis of New Zealand hospitalized patients revals nine predictors of inpatient flare for people with comorbid gout.

This retrospective cohort study of hospitalised patients with comorbid gout included 625 hospitalised patients, 87 experienced inpatient gout flare.

There were 9 predictors of an inpatient gout flare:

Pegradicase+ImmTOR SEL-212 Shows Promising Results In Active Gout

Therapies targeting sUA accumulation or improving its excretion are widely used for treatment of symptoms and prevention of progression of gout for decades. Despite our best effort, there is still a significant amount of patients who remain symptomatic and/or experiences progressive joint damage and disability. Regardless of the cause, either its lack of compliance or poor tolerability, more effective treatments are needed.